^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Melanoma
    Drug:Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lancet Oncol
    Title:

    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Excerpt:
    Encorafenib plus binimetinib and encorafenib monotherapy showed favourable efficacy compared with vemurafenib.
    DOI:
    10.1016/S1470-2045(18)30142-6
    Trial ID:
    COLUMBUS; 2013-001176-38
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

    Excerpt:
    ...Presence of BRAF V600E or V600K mutation in tumor tissue prior to randomization...
    Trial ID:
    COLUMBUS
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Oncotarget
    Title:

    Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

    Published date:
    08/25/2020
    Excerpt:
    BRAF V600E-mutated colorectal (WiDr, RKO, Colo 201, and LS411N) and melanoma (G361 and A375) cell lines were treated with each drug covering a 10,000-fold concentration range....Encorafenib was significantly more effective than vemurafenib in 4 out of 6 cell lines (P = 0.0023 LS411N, P = 0.0002 WiDr, P < 0.0001 A375 and Colo 201).
    DOI:
    https://doi.org/10.18632/oncotarget.27681